-
EP4137585
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4137585
| EP4137585 - CANCER INFORMATIVE BIOMARKER SIGNATURE [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 05.01.2024 Database last updated on 03.09.2024 | |
| Former | The application has been published Status updated on 20.01.2023 | Most recent event Tooltip | 05.01.2024 | Application deemed to be withdrawn | published on 07.02.2024 [2024/06] | Applicant(s) | For all designated states Institut D'Investigacions Biomèdiques August Pi I Sunyer - IDIBAPS C/Rosselló 149-153 08036 Barcelona / ES | For all designated states Universitat de Barcelona Centre de Patents de la UB Baldiri Reixac 4 - Torre D 08028 Barcelona / ES | For all designated states Hospital Clínic de Barcelona C/ Villaroel, 170 08036 Barcelona / ES | For all designated states Consejo Superior de Investigaciones Científicas (CSIC) C/ Serrano 117 28006 Madrid / ES | For all designated states Institució Catalana De Recerca I Estudis Avançats (ICREA) Passeig Lluís Companys, 23 08010 Barcelona / ES | [2023/08] | Inventor(s) | 01 /
MAUREL SANTASUSANA, Joan BARCELONA / ES | 02 /
CASCANTE SERRATOSA, Marta BARCELONA / ES | 03 /
PEDROSA EGUILAZ, Leire BARCELONA / ES | 04 /
FOGUET COLL, Carles BARCELONA / ES | 05 /
THOMSON OKATSU, Timothy BARCELONA / ES | 06 /
POSTIGO, Antonio BARCELONA / ES | 07 /
BENITEZ, Daniel BARCELONA / ES | 08 /
CAMPS POLO, Jordi BARCELONA / ES | [2023/08] | Representative(s) | ZBM Patents - Zea, Barlocci & Markvardsen Rambla de Catalunya, 123 08008 Barcelona / ES | [N/P] |
| Former [2023/08] | ZBM Patents - Zea, Barlocci & Markvardsen Rambla Catalunya, 123 08008 Barcelona / ES | Application number, filing date | 21382772.8 | 20.08.2021 | [2023/08] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP4137585 | Date: | 22.02.2023 | Language: | EN | [2023/08] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 24.02.2022 | Classification | IPC: | C12Q1/6886 | [2023/08] | CPC: |
C12Q1/6886 (EP);
C12Q2600/106 (EP);
C12Q2600/158 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/08] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | KREBSINFORMATIONSBIOMARKERSIGNATUR | [2023/08] | English: | CANCER INFORMATIVE BIOMARKER SIGNATURE | [2023/08] | French: | SIGNATURE DE BIOMARQUEURS INFORMATIFS DU CANCER | [2023/08] | Examination procedure | 23.08.2023 | Application deemed to be withdrawn, date of legal effect [2024/06] | 13.09.2023 | Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time [2024/06] | Fees paid | Penalty fee | Additional fee for renewal fee | 31.08.2023 | 03 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [IA]WO2019090263 (GENENTECH INC [US], et al) [I] 10-12 * abstract * [A] 1-9,13; | [IA] - MARK AYERS ET AL, "IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade", THE JOURNAL OF CLINICAL INVESTIGATION, GB, (20170801), vol. 127, no. 8, doi:10.1172/JCI91190, ISSN 0021-9738, pages 2930 - 2940, XP055608325 [I] 10-12 * abstract * * page 2932, column 2 - page 2933, column 2 * [A] 1-9,13 DOI: http://dx.doi.org/10.1172/JCI91190 | [IA] - LI YING ET AL, "A Novel Prognostic Signature Based on Metabolism-Related Genes to Predict Survival and Guide Personalized Treatment for Head and Neck Squamous Carcinoma", FRONTIERS IN ONCOLOGY, (20210614), vol. 11, doi:10.3389/fonc.2021.685026, XP055891972 [I] 10-12 * abstract * * page 9, columns 1-2 * [A] 1-9,13 DOI: http://dx.doi.org/10.3389/fonc.2021.685026 | [T] - PEDROSA L, "An immune-metabolic signature correlates with immunesuppressive patterns and with outcome, across tumor types", ANNALS OF ONCOLOGY, (20210901), vol. 32, suppl. 5, doi:10.1016/j.annonc.2021.08.1380, page S847, XP055892357 [T] * abstract * DOI: http://dx.doi.org/10.1016/j.annonc.2021.08.1380 | by applicant | US7473767 | - BURTIS C. A. et al., Statistical Treatment of Reference Values, (20080000), vol. Chapter 14 | - CRISTESCU R. et al., "Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy", Science, (20180000), vol. 362, page 3593 | - CHAROENTONG P. et al., "Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade", Cell Rep., (20170103), vol. 18, no. 1, doi:10.1016/j.celrep.2016.12.019, pages 248 - 262, XP055532384 DOI: http://dx.doi.org/10.1016/j.celrep.2016.12.019 | - MARABELLE A. et al., "Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study", Lancet Oncol., (20200000), vol. 21, no. 10, doi:10.1016/S1470-2045(20)30445-9, pages 1353 - 1365, XP086271665 DOI: http://dx.doi.org/10.1016/S1470-2045(20)30445-9 | - PARE L. et al., "Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types", Ann Oncol., (20180000), vol. 29, no. 10, pages 2121 - 2128 | - SHITARA K et al., "Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial", JAMA Oncol, (20201001), vol. 6, no. 10, pages 1571 - 1580 |